Antenatal Magnesium for Preterm Delivery Reduces Risk of Cerebral Palsy Among Surviving Very Preterm Infants

Magnesium sulfate is commonly used antenatally in mothers at high risk of preterm delivery. This randomized controlled trial tested the effectiveness of antenatal magnesium sulfate administration to prevent cerebral palsy in neonates born at 24-31 weeks gestational age. The trial found that compared to placebo, magnesium sulfate treatment reduced the incidence of CP in preterm neonates at 2 years of age. While further study is necessary to streamline treatment recommendations and address effectiveness in preterm infants <24 weeks gestational age, magnesium sulfate is effective in reducing the incidence of cerebral palsy in preterm infants.

Late Neuroimaging Predicts Neurodevelopmental Impairment at 18-22 Months in Preterm Infants Born at 24-27 Completed Weeks’ Gestation

CRANIAL ULTRASOUND Neurodevelopmental impairment is a common morbidity of preterm birth. This prospective cohort study sought to determine the accuracy of cranial ultrasound (CUS) and/or MRI in predicting NDI at 18-22 months of age. Near-term CUS was the most effective predictor of NDI, however likelihood ratios show that no imaging study provides overwhelming predictive power. Thus, the limitations of these studies must be understood before they are widely used as a useful prognostic tool.